Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
Vaxart (OTCQX: VXRT) will present at the virtual Global BioInnovation Forum on Tuesday, January 13, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vaxart (OTCQX: VXRT) will present at the virtual Global BioInnovation Forum on Tuesday, January 13, 2026. Senior leaders speaking are Steven Lo (CEO), Sean Tucker, Ph.D. (Founder & Chief Scientific Officer) and James F. Cummings, M.D. (Chief Medical Officer).
The presentation is scheduled for 11:30am PT / 2:30pm ET. A live webcast will be available via the company's investor relations website and will remain accessible for 30 days after the event.
Details
News Market Reaction – VXRT
On Jan 9, the first trading day after this news, VXRT closed 41.70% above the previous close.
Data tracked by StockTitan Argus for the Jan 9 session.
Key Figures
- Forum date
- January 13, 2026
- Global BioInnovation Forum presentation date
- Presentation time PT
- 11:30 a.m. PT
- Start time of VXRT presentation
- Presentation time ET
- 2:30 p.m. ET
- Start time of VXRT presentation
- Webcast availability
- 30 days
- Replay period on investor relations website
Historical Context
-
Q3 2025 results plus Dynavax collaboration and COVID-19 trial milestones.
-
Announcement of Q3 earnings call and stockholder fireside chat.
-
Phase 1 data on second-generation norovirus oral pill vaccine at IDWeek 2025.
-
Showcase of norovirus and COVID-19 oral pill vaccines at World Vaccine Congress.
-
Withdrawal of reverse stock split proposal after shareholder feedback.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
recombinant medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will participate in the Global BioInnovation Forum, a virtual gathering of senior leaders building and scaling next-generation life science and health innovation companies.
Presentation Details:
Speakers: Steven Lo, Chief Executive Officer, Sean Tucker, Ph.D., Founder and Chief Scientific Officer, and James F. Cummings, M.D., Chief Medical Officer
Date: Tuesday, January 13, 2026
Time: 11:30am PT, 2:30pm ET
Registration and Webcast: Click Here
The webcast will be available on the Company’s investor relations website at https://investors.vaxart.com for 30 days following the conclusion of the event.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact:
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.